Blog
RSS FeedPosted by Michael Wonder on 21 Aug 2024
Dying patients up for $4,000 painkillers in drug supply crisis
21 August 2024 - Dying patients may have to pay more than $4,000 for a box of imported pain-killing tablets ...
Posted by Michael Wonder on 17 Aug 2024
Intravenous scandal escalates: the excuses are fluid
15 August 2024 - A shortage of intravenous IV fluid bags that is causing chaos in Australian hospitals is being ...
Posted by Michael Wonder on 03 Aug 2024
Wegovy, a weight loss drug similar to Ozempic, will be sold in Australia from August 5
3 August 2024 - A drug that mimics popular weight loss medicine Ozempic will be available in Australian pharmacies within ...
Posted by Michael Wonder on 22 May 2024
Protecting Australians from unsafe compounding of replica weight loss products
22 May 2024 - The Albanese Government is acting to protect Australians from the risks posed by injecting potentially unsafe ...
Posted by Michael Wonder on 16 Apr 2024
Norgine submits marketing authorisation application via Project Orbis for eflornithine (difluoromethylornithine) in high-risk neuroblastoma
15 April 2024 - Norgine today announced its first marketing authorisation application submissions on 10 April 2024, seeking approval for eflornithine ...
Posted by Michael Wonder on 29 Feb 2024
Regulator acts to close loophole enabling Australian pharmacists to make copycat Ozempic drug
29 February 2024 - The TGA will move to ban compounding pharmacists from making their own versions of injectable weight ...
Posted by Michael Wonder on 24 Feb 2024
Shortage of migraine medication crushing for chronic pain patients
23 February 2024 - A migraine medication shortage has spread across the country, threatening to leave tens of thousands of ...
Posted by Michael Wonder on 22 Feb 2024
TGA approves new medication for treatment of endometriosis symptoms
23 February 2024 - Australian drug regulator gives company green light for tablet – although it won’t be subsidised by Pharmaceutical ...
Posted by Michael Wonder on 03 Dec 2023
Junshi Biosciences announces new chemical entity application for toripalimab accepted by Australia’s TGA
1 December 2023 - Shanghai Junshi Biosciences announced that the TGA has accepted the new chemical entity application for toripalimab in ...
Posted by Michael Wonder on 12 Nov 2023
MedChem a game changer in identifying lifesaving new drugs
8 November 2023 - The Australian Government is ensuring the next generation of lifesaving drugs and world-class medical treatments can be ...
Posted by Michael Wonder on 04 Nov 2023
Hormone replacement therapy patch shortages are having a big impact on the women who need them
4 November 2023 - Women are being thrust back into the most severe stages of menopause amid long-running national shortages of ...
Posted by Michael Wonder on 28 Sep 2023
Akebia announces approval of Vafseo (vadadustat) in Australia
26 September 2023 - Akebia Therapeutics today announced that Australia's TGA has granted approval for Vafseo (vadadustat), an oral hypoxia-inducible ...
Posted by Michael Wonder on 24 Sep 2023
New rules for weight loss ‘wonder drug’ after regulator clamp down
23 September 2023 - Australia’s pharmaceuticals regulator has ushered in new rules for a diabetes drug, which is being hailed by ...
Posted by Michael Wonder on 01 Sep 2023
Celltrion applies for Australian approval for Stelara biosimilar
31 August 2023 - Celltrion said it has completed a marketing authorisation application for CT-P43, a biosimilar referencing Stelara (ustekinumab) ...
Posted by Michael Wonder on 12 Jul 2023
Idefirix (imlifidase) receives provisional approval in Australia as desensitisation treatment in highly sensitised patients prior to kidney transplantation
11 July 2023 - Regulatory milestone marks the first time Idefirix has been approved in kidney transplantation from both living ...